Omeros

OMER Rare disease Lead: Approved 10 Biotech Distilled articles ↓

Most recent annual filing: 2026-01-15

Catalyst timeline

YARTEMLEA narsoplimab EU decision3Q 2026YARTEMLEA narsoplimab EU decision, 3Q 2026, material
OncotoX-AML trial startlate 2027OncotoX-AML trial start, late 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

YARTEMLEA

narsoplimab · narsoplimab-wuug · OMS721

Protein Target: MASP-2

Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Approved NCT02222545

YARTEMLEA

narsoplimab · OMS721 · narsoplimab-wuug

Protein Target: MASP-2

Acute Respiratory Distress Syndrome Phase 2

OMS1029

Protein Target: MASP-2

Undisclosed indication Phase 1 subcutaneous

OMS527

Small Molecule Target: PDE7

Cocaine Use Disorder Phase 1 oral National Institute on Drug Abuse
Levodopa-Induced Dyskinesia Preclinical Emory University

OncotoX-AML

Protein

Acute Myeloid Leukemia Preclinical

Technology platforms

T-CAT

Targeted complement activating therapy — a new class of recombinant antibodies designed to harness complement activation to kill pathogens directly, including bacteria, fungi, viruses, and parasites; focus on drug-resistant organisms and multidrug-resistant organisms; infectious disease treatment

OncotoX-AML

Novel oncology platform targeting acute myeloid leukemia; lead candidate OMS805 demonstrated superior efficacy to AML standards of care across tumor-bearing animal models and in vitro human AML cell-line studies, independent of AML-related genetic mutations

Biotech Distilled coverage (10)

2026-08-13 UPDATE: Omeros (OMER) — The Slope Question Gets Answered 🔒 Paid
2026-08-03 UPDATE: Omeros (OMER) — NTAP Lands, and It’s Bigger Than I Modeled 🔒 Paid
2026-07-06 UPDATE: Omeros (OMER) — Round Two on the Convert, and a Hint About Non-Dilutive Debt 🔒 Paid
2026-06-26 UPDATE: Omeros (OMER) — CHMP Says No, Re-Examination Coming 🔒 Paid
2026-06-18 UPDATE: Omeros (OMER) — Buying Back the Convert at 2x Face 🔒 Paid
2026-05-14 UPDATE: Omeros (OMER) - First Launch Quarter Prints $9.9M, NTAP Tailwind Stacks on the J-Code 🔒 Paid
2026-04-18 UPDATE: Omeros (OMER) – Permanent J-Code Clears the Runway 🔒 Paid
2026-04-05 UPDATE: Omeros (OMER) – Q4/YE 2025 Earnings, Launch Strategy, and Pipeline Nuance 🔒 Paid
2026-02-21 UPDATE: Omeros (OMER) - OncotoX Platform Shows Proof of Concept 🔒 Paid
2025-12-26 Omeros Corporation (OMER): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.